© 2022 MJH Life Sciences and CGTLive™. All rights reserved.
© 2022 MJH Life Sciences™ and CGTLive™. All rights reserved.
June 11, 2017
This video reviews results of LUX-Head & Neck 2, a randomized phase III trial that studied afatinib as adjuvant therapy in patients with unresected squamous cell head and neck cancer.